Changes in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113.

TitleChanges in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113.
Publication TypePublication
Year of Publication2020
AuthorsHavens PL, Perumean-Chaney SE, Patki A, Cofield SS, Wilson CM, Liu N, Anderson PL, Landovitz RJ, Kapogiannis BG, Hosek SG, Mulligan K
JournalClin Infect Dis
Volume70
Issue4
Pagination687-691
Date Published2020 Feb 03
ISSN1537-6591
KeywordsAdolescent, Adult, Anti-HIV Agents, Bone Density, Emtricitabine, HIV Infections, Homosexuality, Male, Humans, Male, Pre-Exposure Prophylaxis, Sexual and Gender Minorities, Tenofovir, Young Adult
Abstract

<p>Human immunodeficiency virus-seronegative men aged 15-22 years who lost bone mineral density (BMD) during tenofovir disoproxil fumarate/emtricitabine preexposure prophylaxis (PrEP) showed BMD recovery 48 weeks following PrEP discontinuation. Lumbar spine and whole body BMD z-scores remained below baseline 48 weeks off PrEP in participants aged 15-19 years. Clinical Trials Registration. NCT01772823 (ATN 110) and NCT01769456 (ATN 113).</p>
DOI10.1093/cid/ciz486
Alternate JournalClin Infect Dis
PubMed ID31179503
PubMed Central IDPMC7319267